Dr Abby Statler: African American Patients With AML Exhibit Higher Kidney Test Abnormalities
February 26th 2020When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results–these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
Watch
Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials
February 21st 2020Our outcomes suggest that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities may be relaxed, especially for those who have minor renal function abnormalities who have shown to have similar clinical outcomes to those without such abnormalities, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
Watch
Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials
January 3rd 2020In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
Watch